Helus Pharma Rebrands, Debuts On Nasdaq

KUALA LUMPUR, Jan 6 (Bernama) -- Helus Pharma, formerly Cybin Inc, marked its transition toward commercialisation as it began trading on the Nasdaq Global Market and Cboe Canada under the ticker symbol HELP, reflecting a strategic rebrand and corporate repositioning.

The clinical-stage pharmaceutical company in a statement said the Helus Pharma identity builds on Cybin’s foundation while underscoring its evolution into a commercial-ready drug developer focused on novel serotonergic agonists (NSAs) aimed at redefining mental health care.

Its interim chief executive officer, Eric So said the rebrand reflects the company’s readiness to move beyond discovery and development toward market delivery, supported by a robust intellectual property portfolio comprising more than 350 filed patents.

He added that key clinical milestones anticipated in 2026 position the company to introduce differentiated therapies, enhance patient outcomes, and generate long-term value for healthcare stakeholders and shareholders.

Shares now trade on Nasdaq following a transfer from the NYSE American, while the company maintains its Cboe Canada listing under the same ticker. Helus Pharma plans to seek shareholder approval to formally change its legal name at its next annual and special meeting.

Helus Pharma’s lead programme, HLP003, is in Phase 3 development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the United States Food and Drug Administration. Preparations for commercialisation are underway, subject to regulatory approvals.

The company is also advancing HLP004, an NSA in a Phase 2 study for generalised anxiety disorder, with topline data expected in the first quarter of 2026.

-- BERNAMA